pharmaceutical business development
CASE STUDIES
A Romanian pharmaceutical company wanted business development support. Find out how we helped >>
A university wanted a commercial appraisal and valuation of an antibody technology. Find out more >>
A biotech company’s business development resources were stretched. We provided interim management support >>
The Government of Egypt wanted a thorough strategic review and benchmarking of their pharmaceutical industry. Find out more >>
© Estradia Consulting Limited. All rights reserved. Privacy Policy. Terms of use.
WHAT A SATISFIED CLIENT SAYS
“Many thanks indeed for a superbly compiled commercial appraisal...I've never been less than fully satisfied with your superbly crafted reports.”
Dr Albert Chan
Overseas Markets Director
Special Products Limited
+ 44 (0) 1252 714 221
RECENT PROJECTS
We have worked with many international clients ranging from individual entrepreneurs and small companies through to pharmaceutical companies and governments. We always strive to add value with what we do and only take on projects where we have the experience and skills required. Below are some examples of recent projects.
Case Study 5
An entrepreneur wanted to raise money to start a new respiratory products company. She was an experienced medical doctor but had limited business skills.
We worked with her to help her to prepare a robust business plan, to budget for the
business start-
Case Study 6
A small early stage company developing a novel vaccine technology wanted advice on the licensing terms for allowing manufacturers to access their technology.
We prepared a draft licensing agreement for the company highlighting the areas that they needed to focus on during their negotiations with manufacturers. Through our extensive contacts in the international licensing field we were able to benchmark expected fees for technology access.
Case Study 7
A small company which sold unlicensed medicines wanted to develop its business outside
of UK.
We were able to identify the different regulatory environments for unlicensed
medicines in other European countries. We subsequently identified potential distributors
in the target countries and rapidly negotiated and concluded commercial terms.
Case Study 8
A pharmaceutical company had a novel formulation of an established neurology product in Phase I of development. Future development costs were higher than expected, and the company wanted an independent valuation of the market potential before deciding whether to commit to development.
Our appraisal of the market identified that the target indication was too small to justify development of the product, as this would involve a high risk with little opportunity for a return on the investment. However our analysis also revealed that the product was likely to be effective in several much larger market sectors. Following our discounted cash flow and Net Present Value analysis the company decided to focus the development on the newly identified target indications.